The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on ALX Oncology Holdings' stock price. The analyst's continued bullish stance suggests a strong belief in the company's potential, which can influence investor sentiment positively.